Clinical trial
A Phase I/II Study to Assess the Safety,Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Patients With Locally Advanced or Metastatic T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
NCT03502850 is registered in ClinicalTrials.gov with Jiangsu Aosaikang Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study to Assess the Safety,Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Patients With Locally Advanced or Metastatic T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent
- Lead sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- November 30, 2017
- Completion date
- August 31, 2021
- Enrollment
- 507 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced or metastatic nsclc